Current cholesterol guidelines promote the use of statins as first line therapy in primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) events. Despite the impressive risk reduction associated with statins, a 60% to 80% residual risk of vascular events remains. Does adding niacin to statin treatment reduce residual risk? Or does statin therapy alone offer optimal benefit?
Primary prevention trials of statins have shown they can reduce the... Read More
The treatment options for type 2 diabetes mellitus (T2DM) have increased dramatically over the past decade. Despite these advancements, treatment recommendations remain largely unchanged. The American Diabetes Association (ADA) recommends that patients newly diagnosed with T2DM modify their diet, exercise, and take oral medication (i.e. metformin). Only later should injectable therapies be considered. Until recently, the ADA’s treatment algorithm recommended basal-bolus insulin... Read More
Achieving provider status has been the latest buzz for many pharmacy organizations over the past year. Provider status will likely lead to increased access to pharmacists' services in the ambulatory care setting and inclusion of medication therapy management by pharmacists as an essential benefit in emerging healthcare delivery models. Arguably the most important goal in achieving provider status is payment for pharmacists' patient care services under Medicare Part B. The key to... Read More